Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

British Journal of Cancer

Volumn 102, Issue 1, 2010, Pages 59-67

  Conroy, T ^a   Hebbar, M ^b   Bennouna, J ^c   Ducreux, M ^d   Ychou, M ^e   Lledo G ^f   Adenis, A ^g   Faroux, R ^h   Rebischung, C ⁱ   Kockler, L ^j   Douillard, J Y ^b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e CENTRE VAL D AURELLE   (France)

^f Clinique Saint Jean   (France)

^g CENTRE OSCAR LAMBRET   (France)

^h Centre Hospitalier Departemental   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j Laboratoires Roche   (France)

more..

Author keywords

Capecitabine; CCSQ FACIT; Colorectal cancer; QLQ C30; QoL

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 74249098021     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605442     Document Type: Article

References (42)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14: 671-679
3. Beitz J, Gnecco C, Justice R (1996) Quality-of-life end points in cancer clinical trials: the US Food and Drug Administration perspective. J Natl Cancer Inst Monogra 20: 7-9
4. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349-358
5. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488
6. Cassidy J, Clarke S, D́iaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L (2008) A randomized phase III study of capecitabine plus oxaliplatin (XELOX) versus fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006-2012
7. Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, D́iaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP (2006) Pharmacoeconomic analysis of adjuvant oral capecitabine versus intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 94: 1122-1129
8. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, Mckendrick J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann Oncol 13: 566-575
9. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, D́iaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091
10. Conroy T, Guillemin F, Kaminsky MC (2002) Measure of quality of life in patients with metastatic colorectal cancer: techniques and main results. Rev Med Interne 23: 703-716
11. Conroy T, Mercier M, Bonneterre J, Luporsi E, Lefebvre JL, Lapeyre M, Puyraveau M, Schraub S (2004) French version of FACT-G: validation and comparison with other cancer-specific instruments. Eur J Cancer 40: 2243-2252
12. Cronbach LJ (1951) Coefficient alpha and internal structure of tests. Psychometrika 16: 297-334
13. D́iaz-Rubio E, Tabernero J, Góómez-España A, Massut́i B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E (2007) Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 25: 4224-4230
14. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis A, Faroux R, Rebischung C, Douillard JY (2007). Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxiplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 25 (18S) (Suppl. Part I): 170s: abstract 4029
15. Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, Van Cutsem E, Köhne CH (2006) Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 42(1): 42-49. [published erratum appears in: Eur J Cancer 2007; 43: 633]
16. Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F (2008) Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 26: 2020-2026
17. European Medicines Agency. Committee for medicinal products for human use (2005) Guideline on the evaluation of anticancer medicinal products in man. Available at: http://www.emea.europa.eu/pdfs/human/ewp/ 020595en.pdf
18. European Organization for Research and Treatment of Cancer (2008) EORTC QLQ-C3. Available at: http://groups.eortc.be/qol/questionnaires- qlqc30.htm
19. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A on behalf of the EORTC Quality of Life Group (2001) EORTC QLQ-C30 Scoring Manual. (3rd edn). European Organization for Research and Treatment of Cancer: Brussels. http://groups.eortc.be/qol/documenta tion-manuals.htm
20. Fayers P, Bottomley A (2002) Quality of life research within the EORTC-the EORTC QLQ-C30. Eur J Cancer 38: S125-S133
21. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR (2002) Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77: 371-383
22. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292 (Pubitemid 32366981)
23. Köhne CH, Cunningham D, Di Costanzo Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308-317
24. Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N (2007) Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 25: 424-430, [published erratum appears in: J Clin Oncol 2007; 25: 5540-5541]
25. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281
26. Nunally JC, Berstein IH (1994) Psychometric Theory. 3rd edn. New York: McGrawHill
27. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16: 139-144
28. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
29. Payne SA (1992) A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35: 1505-1509
30. Pelusi J (2006) Capecitabine versus 5-FU in metastatic colorectal cancer: considerations for treatment decision-making. Commun Oncol 3: 19-27
31. Perrocheau G, Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, Conroy T, Dominguez S, Florentin V, Douillard JY (2009) Cost-minimization analysis of XELOX versus FOLFOX-6 as first-line treatment of metastatic colorectal cancer in France. American Society of Clinical Oncology, Gastrointestinal cancers symposium: San Francisco Abstract, #10411, p 290
32. Porschen R, Arkenau H-T, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll H-J (2007) Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: a randomized comparison in metastatic colorectal cancer-a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223
33. Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40: 85-104
34. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S, Cunningham D (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19: 1720-1726
35. Rotonda C, Conroy T, Mercier M, Bonnetain F, Uwer L, Miny J, Montcuquet P, Léonard I, Adenis A, Breysacher G, Guillemin F (2008) Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C. Qual Life Res 17: 437-445
36. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297
37. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92: 205-216 (Pubitemid 30099779)
38. Twelves C, Gollins S, Grieve R, Samuel L (2006) A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 17: 239-245, Comment in: Ann Oncol 2006;17:185-187
39. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, Mckendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz J-F, Thompson P, Vieitez JM, Harper P, Weitzel C (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106
40. Webster K, Cella D, Yost K (2003) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1: 79
41. Yost K, Hahn E, Cella D (2005a) A new measure of chemotherapy convenience and satisfaction. J Clinic Oncol 23: 538s
42. Yost KJ, Cella D, Chawla A, Holmgren E, Eton DT, Ayanian JZ, West DW (2005b) Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution-and anchor-based approaches. J Clin Epidemiol 58: 1241-1251